RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재후보 SCOPUS

      연구자가 스폰서 주도 임상 시험에 참여하는 이유 = Reasons for Investigators to Participate Industry Sponsored Clinical Trials

      한글로보기

      https://www.riss.kr/link?id=A104760667

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Background: It is getting more difficult to involve appropriate investigators in clinical trials.
      Knowing what investigators want from sponsor initiated clinical trials would help industry cooperate with investigators more efficiently. This study aims to describe the incentives for investigators choosing to participate or not and perform well in sponsored clinical trials.
      Methods: Investigators who have participated in GSK sponsored clinical trials were interviewed face-to-face or through e-mail using the standardized questionnaire. Investigators were asked to choose five items and determine the ranking or those five items Results: Questionnaires answered by 122 investigators were collected. The top three incentives were "Academic merit" (108, 88.5 %), "Expectation of treatment potentially helpful to patient" (101, 82.8 %),and "Access to new treatments" (92, 75.4 %). The disincentives and the factors affecting an investigator’s performance were analyzed separately because of the different questionnaire between investigators for medicine and vaccine. Investigators for medicine choose as disincentives "Insufficient time" (43, 61.4 %), "Difficult protocol" (41, 58.6 %), and "Adverse event concerns" (41, 58.6 %). Vaccine investigators pointed out "Limited support staff" (41, 78.8 %), "Insufficient time" (40, 76.9 %), and "Difficult blood sampling" (333, 63.5 %) as disincentives. Factors adversely affecting an investigator’s performance showed similar results to those of disincentives.
      Conclusion: Investigators focused on academic curiosity and patients and insufficient time mostly inhibits them from participating and performing clinical trials. Our results would help industry cooperate with investigators more efficiently, finally making companies perform clinical trials more effectively.
      번역하기

      Background: It is getting more difficult to involve appropriate investigators in clinical trials. Knowing what investigators want from sponsor initiated clinical trials would help industry cooperate with investigators more efficiently. This study aims...

      Background: It is getting more difficult to involve appropriate investigators in clinical trials.
      Knowing what investigators want from sponsor initiated clinical trials would help industry cooperate with investigators more efficiently. This study aims to describe the incentives for investigators choosing to participate or not and perform well in sponsored clinical trials.
      Methods: Investigators who have participated in GSK sponsored clinical trials were interviewed face-to-face or through e-mail using the standardized questionnaire. Investigators were asked to choose five items and determine the ranking or those five items Results: Questionnaires answered by 122 investigators were collected. The top three incentives were "Academic merit" (108, 88.5 %), "Expectation of treatment potentially helpful to patient" (101, 82.8 %),and "Access to new treatments" (92, 75.4 %). The disincentives and the factors affecting an investigator’s performance were analyzed separately because of the different questionnaire between investigators for medicine and vaccine. Investigators for medicine choose as disincentives "Insufficient time" (43, 61.4 %), "Difficult protocol" (41, 58.6 %), and "Adverse event concerns" (41, 58.6 %). Vaccine investigators pointed out "Limited support staff" (41, 78.8 %), "Insufficient time" (40, 76.9 %), and "Difficult blood sampling" (333, 63.5 %) as disincentives. Factors adversely affecting an investigator’s performance showed similar results to those of disincentives.
      Conclusion: Investigators focused on academic curiosity and patients and insufficient time mostly inhibits them from participating and performing clinical trials. Our results would help industry cooperate with investigators more efficiently, finally making companies perform clinical trials more effectively.

      더보기

      참고문헌 (Reference)

      1 이상명, "의료기관의 임상시험 현황과 활성화 방안: 2003년 연구와 비교를 중심으로" 대한임상약리학회 16 (16): 101-110, 2008

      2 Karlberg JP, "Magnifier subscriber survey - incentives for participation in industry Sponsored Clinical Trials" 2 (2): 37-51, 2009

      3 Karlberg JP, "Industry sponsored clinical trials in South Korea" 1 (1): 179-194, 2008

      4 Rendell JM, "Incentives and disincentives to participation by clinicians in randomised controlled trials" 18 (18): 1-25, 2007

      5 Brandt S, "How to design a successful disease-management program"

      1 이상명, "의료기관의 임상시험 현황과 활성화 방안: 2003년 연구와 비교를 중심으로" 대한임상약리학회 16 (16): 101-110, 2008

      2 Karlberg JP, "Magnifier subscriber survey - incentives for participation in industry Sponsored Clinical Trials" 2 (2): 37-51, 2009

      3 Karlberg JP, "Industry sponsored clinical trials in South Korea" 1 (1): 179-194, 2008

      4 Rendell JM, "Incentives and disincentives to participation by clinicians in randomised controlled trials" 18 (18): 1-25, 2007

      5 Brandt S, "How to design a successful disease-management program"

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2014-12-23 학술지명변경 한글명 : 임상약리학회지 -> Translational and Clinical Pharmacology
      외국어명 : The Journal of Korean Society for Clinical Pharmacology and Therapeutics -> Translational and Clinical Pharmacology
      KCI등재
      2013-10-01 평가 등재학술지 선정 (기타) KCI등재
      2011-01-01 평가 등재후보학술지 유지 (기타) KCI등재후보
      2007-01-01 평가 SCOPUS 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.07 0.07 0.05
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.05 0.05 0.3 0.03
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼